SAGE - Sage Therapeutics falls after stock offering Q3 miss
2023-11-07 08:30:19 ET
More on Sage Therapeutics
- Sage Therapeutics: Several Neuropsychiatric Disorder Data Readouts In 2024
- Sage Therapeutics: Undeserving Selloff Presents A Buying Opportunity
- Sage Therapeutics Q3 2023 Earnings Preview
- Sage granted FDA orphan tag for Huntington’s disease therapy
- Seeking Alpha’s Quant Rating on Sage Therapeutics
For further details see:
Sage Therapeutics falls after stock offering, Q3 miss